GlassScriptPhysician profile
Syed W Rizvi
NPI 1275573321
$9,538.47
in general payments reported to CMS, 2019-2025
51 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,367 · 2020: $1,445 · 2021: $1,416 · 2022: $1,216 · 2023: $698 · 2024: $818 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,078 · Education: $15.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.07 |
| Education | $15.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,277.27 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $1,203.94 | 2019-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $985.41 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $549.03 | 2019-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $525.20 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Kowa Pharmaceuticals America, INC. | $434.55 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $419.87 | 2022-2025 | |
| Corcept Therapeutics | $349.54 | 2019-2025 | Korlym |
| Amgen INC. | $309.29 | 2019-2025 | Tepezza, Repatha, Repatha |
| Xeris Pharmaceuticals, INC. | $308.09 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $289.18 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $281.26 | 2025 | Yorvipath |
| Abbvie INC. | $225.75 | 2019-2024 | Synthroid, Ubrelvy |
| Abbott Laboratories | $190.20 | 2019-2025 | Freestyle Libre 3 |
| Endo Pharmaceuticals INC. | $189.12 | 2019-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.